10 results
Oral Anticoagulation - VTE and DVT Bridging

- Amelia Furbish PharmD Student @ https://www.instagram.com/happypillsrx/

#DOAC #Oral #Anticoagulant #VTE
- VTE and DVT Bridging ... happypillsrx/ #DOAC ... Anticoagulant #VTE #DVT #Bridging
Oral anticoagulant dosing and bridging for VTE

- Dr. Joseph Shatzel @Clotmaster 

#VTE #DOAC #Bridging #Dosing #Oral
anticoagulant dosing and bridging ... Clotmaster #VTE #DOAC ... #Bridging #Dosing
Heparin, Fondaparinux, and Novel Oral Anticoagulants - Pathophysiology

Anticoagulation with parenteral (intravenous or subcutaneous) and oral anticoagulants
Anticoagulants - Pathophysiology ... accelerates the bridging ... #Pharmacology #Pathophysiology ... Heparins #LMWH #UFH #DOAC ... #Fondaparinux #NOAC
Patient risk stratification algorithm for the treatment of cancer-associated thrombosis.

Currently, edoxaban and rivaroxaban are the only
anticoagulants (DOACs ... filtration rate; DOAC ... #DOAC #VTE #Malignancy ... Management #Hematology #Oncology
Anticoagulant Bridging

 • Switching from LMWH
 • Switching from UFH
 • Switching from DOAC to Warfarin
Anticoagulant Bridging ... Switching from DOAC ... from Warfarin to DOAC ... (No Bridging) ... Anticoagulant #Bridging
(DOAC interactions) Cancer-treatment specific inducers (↑) and inhibitors (↓)
of cytochrome p450 CYP3A4 and P-glycoprotein.

DOACs are substrates
(DOAC interactions ... DOACs are substrates ... metabolization of DOACs ... content/133/4/291 #DOAC ... #Chemotherapy #Oncology
Coagulation Cascade and Anticoagulant Sites of Action

- Amy Chung, MD, MSc https://twitter.com/AmyChung

#AntiCoagulation #Cascade #Anticoagulants #Medications #Pharmacology
#Pharmacology #Pathophysiology ... #Mechanisms #DOAC
Treatment algorithm for VTE in Malignancy

(A) Suggested treatment algorithm for symptomatic and incidental DVT or PE
DOAC, direct oral ... #DOAC #VTE #Malignancy ... Management #Hematology #Oncology
Heparin Induced Thrombocytopenia (HIT) - Diagnosis and Management - GrepMed Handbook

Presentation: 
 • Plts ↓50% (nadir
♀, ↑Age, ESRD Pathophysiology ... , Bivalirudin, DOAC
Differentiation Syndrome in APML
Epidemiology:
 • Incidence: common in APL (2-48% depending on the study)
 • Triggers:
ATRA treatment Pathophysiology ... Noah Rosenberg @ ... management #hematology #oncology